PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2021.0236202228191-104A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspectiveHye-Lin Kim, Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Moran Ki, Hwa Young Choi, Sook-Hyang Jeonghttp://e-cmh.org/upload/pdf/cmh-2021-0236.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2021.0236, http://e-cmh.org/upload/pdf/cmh-2021-0236.pdf
Journal of Infection and Public Health10.1016/j.jiph.2018.08.0042019123442-444Cost-effectiveness of EGCRISC application versus hepatitis C virus mass screening in EgyptEngy M. El-Ghitanyhttps://api.elsevier.com/content/article/PII:S1876034118301333?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1876034118301333?httpAccept=text/plain
The Korean Journal of Internal Medicine10.3904/kjim.2013.28.4.4082013284408Hepatitis B virus infection in South Korea: three decades after universal vaccinationJin-Wook Kimhttp://synapse.koreamed.org/pdf/10.3904/kjim.2013.28.4.408, http://synapse.koreamed.org/DOIx.php?id=10.3904/kjim.2013.28.4.408, http://www.kjim.org/upload/kjim-28-408.pdf
Vaccine10.1016/j.vaccine.2009.08.082200927486770-6776Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: An experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalenceHui-Fang Hung, Tony Hsiu-Hsi Chenhttps://api.elsevier.com/content/article/PII:S0264410X09012729?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0264410X09012729?httpAccept=text/plain
BMJ Global Health10.1136/bmjgh-2020-0031942020511e003194Cost-effectiveness of new antiviral treatments for non-genotype 1 hepatitis C virus infection in China: a societal perspectiveXia Wei, Jingyu Zhao, Li Yanghttps://syndication.highwire.org/content/doi/10.1136/bmjgh-2020-003194
Clinical Gastroenterology and Hepatology10.1016/j.cgh.2018.08.0802019175930-939.e9Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment RegimensMark H. Eckman, John W. Ward, Kenneth E. Shermanhttps://api.elsevier.com/content/article/PII:S1542356518309613?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1542356518309613?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(22)00948-5202277S291Time for universal screening for hepatitis D? A study describing screening patterns, characteristics and outcomes of hepatitis D virus infectionRohit Nathani, Bo Hyung Yoon, Carolina Villarroel, Sidra Salman, Dewan Giri, Amreen Dinani, Ilan Weisberghttps://api.elsevier.com/content/article/PII:S0168827822009485?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827822009485?httpAccept=text/plain
Transfusion10.1111/trf.139782017572258-266Cost-effectiveness of the screening of blood donations for hepatitis E virus in the NetherlandsAnneke S. de Vos, Mart P. Janssen, Hans L. Zaaijer, Boris M. Hogemahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ftrf.13978, http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.13978/fullpdf
Transfusion10.1111/trf.1312720155561143-1146Screening blood donors for hepatitis C virus: the challenge to consider cost-effectivenessPhilip Kielyhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Ftrf.13127, http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.13127/fullpdf
The Lancet Global Health10.1016/s2214-109x(21)00517-92022102e278-e287Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluationShu Su, William CW Wong, Zhuoru Zou, Dan Dan Cheng, Jason J Ong, Polin Chan, Fanpu Ji, Man-Fung Yuen, Guihua Zhuang, Wai-Kay Seto, Lei Zhanghttps://api.elsevier.com/content/article/PII:S2214109X21005179?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S2214109X21005179?httpAccept=text/plain